Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019

Table 2 Laboratory findings of complementary system in aHUS patients in our study

		Case 1	Case 2	Case 3	Case 4
1	sC5b-9
	ng/ml	871.1	1144.3	929.2	337.5
	Normal range	37.0–260.6	37.0–260.6	37.0–260.6	37.0–260.6
2	Ba
	ng/ml	n.e.	957.7	7586.0	4373.3
	Normal range		275.6–685.2	275.6–685.2	275.6–685.2
3	CFH
	μg/ml	n.e.	430.0	550.6	247.2
	Normal range		229.8–714.6	229.8–714.6	229.8–714.6
4	CFH-IgG
	AU/ml	n.e.	654.9	915.1	758.3
	Normal range		393.9–1183.0	393.9–1183.0	393.9–1183.0
5	CFI
	μg/ml	n.e.	106.7	62.5	41.0
	Normal range		72.0–139.2	72.0–139.2	72.0–139.2
6	C5a
	ng/ml	n.e.	11.15	5.66	3.48
	Normal range		0.20–15.62	0.20–15.62	0.20–15.62
7	C3
	mg/dl	n.e.	89.2	90.0	51.7
	Normal range		61.3–131.7	61.3–131.7	61.3–131.7
8	C4
	mg/dl	n.e.	13.8	22.3	7.9
	Normal range		8.7–33.1	8.7–33.1	8.7–33.1
9	CH50
	CH50/ml	n.e.	38.1	38.6	29.7
	Normal range		31.2–43.2	31.2–43.2	31.2–43.2
10	C1-inhibitor activity
	%	n.e.	NT	NT	NT
	Normal range	77.6–144.0	77.6–144.0	77.6–144.0	77.6–144.0

ISSN: 2059-1381